Skip to main content

Market Overview

5 Short Squeeze Stocks That Could Soar: NeruoBo Pharmaceuticals, FaZe Holdings And More

Share:
5 Short Squeeze Stocks That Could Soar: NeruoBo Pharmaceuticals, FaZe Holdings And More

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.

Here’s a look at the top five short squeeze candidates for the week of Sept. 19, according to Fintel Data:

NeuroBo Pharmaceuticals: Clinical stage biotechnology company NeuroBo Pharmaceuticals (NASDAQ: NRBO) tops the short squeeze leaderboard for the week of Sept. 19. The company has 36.9% of its float short and a cost to borrow of 148.9%, ranking among the highest for both key factors that can determine how likely a short squeeze is to happen.

Related Link: Apple Overtakes Tesla As The Most Shorted Stock: Here's Why It Matters And Why It Doesn't 

FaZe Holdings: eSports and digital content company FaZe Holdings Inc (NASDAQ: FAZE) moves up eight positions to second place on the leaderboard. Data shows 92.8% of the float short, down from last week’s 149.6% reported. The cost to borrow on shares is 1,058.1%, in line with last week’s report. The stock has been among the top mentioned short squeeze candidates since going public via SPAC.

Minerva Neurosciences: Clinical stage biopharmaceutical company Minerva Neurosciences (NASDAQ: NERV) moves up 120 places on the leaderboard to rank third for the week. Data shows 34.1% of the float short and a cost to borrow of 85.0%.

Greenwich LifeSciences: Clinical stage biopharmaceutical company Greenwich LifeSciences Inc. (NASDAQ: GLSI) is the only top five carryover from last week’s report, moving down one position to fourth place. Data shows 24.8% of the float short, an increase from last week’s 20.8% reported. The cost to borrow of 11.2% on shares remains the same from last week.

SurgePays: Fintech company SurgePays Inc (NASDAQ: SURG) moves up 24 positions to rank fifth on the short squeeze leaderboard for the week. Data sows 54.5% of the float short and a cost to borrow of 7.0%. The company has the fourth-highest short percentage for the week, according to the report and could move up or remain in the top five if the cost to borrow also increases.

 

Related Articles (GLSI + FAZE)

View Comments and Join the Discussion!

Posted-In: Biopharmaceutical Stocks Biotech Stocks eSports FintelNews Penny Stocks Small Cap Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com